Medpace Holdings Inc.

09/20/2024 | Press release | Distributed by Public on 09/20/2024 13:23

[Upcoming Webinar] Innovative Approaches in MASH Clinical Research

The evolving landscape of metabolic dysfunction-associated steatohepatitis (MASH) research demands precise and reliable methodologies to ensure accurate data collection and analysis. In this upcoming webinar, expert speakers will provide a deep dive into the imaging and histological techniques that are foundational to metabolic dysfunction-associated steatohepatitis studies. Attendees will also gain insights into the operational and medical strategies that streamline the research process, ensuring that studies are conducted with the highest level of quality and consistency.

Expert Panelists:

Dr. Salvatore Zabbatino, MD
Senior Director, Core Laboratories, Medpace

Dr. Robert McGee, MD, PhD
Senior Medical Director, Central Laboratories, Medpace

Dr. Nicola Owen, PhD, MBBS
Medical Director, Medpace

Jenson Ruiz Garcia, MSc
Clinical Trial Management, Medpace

Learn from Medpace experts, as they explore strategies to enhance operational efficiency, focusing on ensuring seamless integration of data throughout the study process - from sample collection to final analysis. They will also cover best practices for the preparation and standardization of liver biopsy samples, essential for accurate histological evaluation. This will include detailed guidance on resolving connectivity issues related to transitioning from traditional microscopy to whole-slide digital images. Additionally, the webinar will discuss the evolution of read paradigms, from single to multi-read techniques, and the implications this has for diagnostic accuracy and research outcomes in MASH.

This webinar will thus offer a comprehensive overview from sample acquisition of biopsy samples to final endpoint analysis - emphasizing the importance of maintaining consistency across tissue batches over extended study periods, which is crucial for the integrity of metabolic dysfunction-associated steatohepatitis studies.

Global MASH & MASLD Capabilities

As a therapeutically-aligned CRO, Medpace has the relevant and recent hepatology experience in indications such as metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) to successfully navigate the complexities and regulatory scrutiny often involved with these programs. Our experience, coupled with our strong relationships with KOLs and investigative sites and our in-house central lab and imaging core lab services, set you up for long term success.